Leukemia-targeting NK cell nanoengagers effectively promote robust NK activation and potent anti-acute myeloid leukemia response - PubMed
5 days ago
- #Protein nanoparticles
- #NK cell therapy
- #Acute myeloid leukemia
- Development of leukemia-targeting NK cell nanoengagers (AaLS/aCD16Nb/aCD13Nb) for AML immunotherapy.
- Nanoengagers bind to NK cells and AML cells, enhancing NK activation and IFN-γ production.
- Significant reduction in leukemic burden and extended survival in AML mouse models.
- Potential broad applicability of the dual-ligand-displaying nanoengager platform for other malignancies.